{"id":1327,"date":"2016-10-06T18:07:18","date_gmt":"2016-10-06T12:37:18","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1327"},"modified":"2021-07-24T12:56:33","modified_gmt":"2021-07-24T07:26:33","slug":"business-cocktail-6","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6","title":{"rendered":"Bayer Partners with DelSiTech to Develop; Amgen and Arrowhead Announce; Allergan, AstraZeneca\u2019s deal; Lexicon Pharma announces deal"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f91490549f2\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f91490549f2\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6\/#Bayer_Partners_with_DelSiTech_to_Develop_Innovative_Drug_Delivery_Technology_for_Ophthalmology\" >Bayer Partners with DelSiTech to Develop Innovative Drug Delivery Technology for Ophthalmology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6\/#Amgen_and_Arrowhead_Pharmaceuticals_Announce_Two_Cardiovascular_Collaborations\" >Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6\/#Allergan_AstraZeneca_Enter_Licensing_Agreement_for_MEDI2070\" >Allergan, AstraZeneca Enter Licensing Agreement for MEDI2070<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6\/#Lexicon_Pharma_announces_Agreement_to_Buy_Out_Remaining_Obligations_to_Symphony_Icon\" >Lexicon Pharma announces Agreement to Buy Out Remaining Obligations to Symphony Icon<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Bayer_Partners_with_DelSiTech_to_Develop_Innovative_Drug_Delivery_Technology_for_Ophthalmology\"><\/span>Bayer Partners with DelSiTech to Develop Innovative Drug Delivery Technology for Ophthalmology<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><strong>Bayer <\/strong>has partnered with a Finnish drug delivery and drug developmental company,<strong>DelSiTechLtd<\/strong>., through a Collaboration and Technology Licence Agreement. The agreement gives <strong>Bayer<\/strong>\u2019s compounds a worldwide application of <strong>DelSiTech<\/strong>\u2019s Silica Matrix drug delivery platform, especially in ophthalmology.\u00a0<strong>DelSiTech<\/strong> is entitled to receive a number of undisclosed milestone payments triggered by the successful completion of different stages of development, and <strong>Bayer<\/strong> will fund all developmental and commercialization costs of the collaborative projects.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Amgen_and_Arrowhead_Pharmaceuticals_Announce_Two_Cardiovascular_Collaborations\"><\/span>Amgen and Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">The collaboration of <strong>Amgen<\/strong> and <strong>Arrowhead Pharmaceuticals<\/strong> is for the development and commercialization of RNA interference (RNAi) therapies for cardiovascular disease.Under one agreement, <strong>Amgen<\/strong> receives a worldwide, exclusive license to <strong>Arrowhead<\/strong>&#8216;s novel, RNAi ARC-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein. Under the second agreement, <strong>Amgen<\/strong> receives an option to a worldwide, exclusive license for RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, <strong>Amgen<\/strong> will be wholly responsible for clinical development and commercialization.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Allergan_AstraZeneca_Enter_Licensing_Agreement_for_MEDI2070\"><\/span>Allergan, AstraZeneca Enter Licensing Agreement for MEDI2070<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><strong>Allergan<\/strong> and <strong>AstraZeneca<\/strong> have entered an agreement for the global rights to MEDI2070, an anti-IL-23 monoclonal antibody currently in Phase II development for the treatment of moderate-to-severe Crohn&#8217;s disease and ulcerative colitis and other related conditions. <strong>AstraZeneca<\/strong> will receive $250 million upfront and potential payments of as much as $1.27 billion, including launch milestones of up to $435 million and sales-based milestones of $725 million, as well as royalties on product sales.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Lexicon_Pharma_announces_Agreement_to_Buy_Out_Remaining_Obligations_to_Symphony_Icon\"><\/span>Lexicon Pharma announces Agreement to Buy Out Remaining Obligations to Symphony Icon<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\"><strong>Lexicon Pharmaceuticals, Inc.<\/strong> has announced that it has entered into an agreement to buy out its remaining obligations under its clinical development financing arrangement with <strong>Symphony Icon Holdings LLC<\/strong> upon regulatory approval in the United States for the marketing and sale of telotristat ethyl. Under the buyout arrangement, <strong>Lexicon<\/strong> will make a single payment to <strong>Symphony Icon<\/strong> of $21.013 million upon U.S. regulatory approval of telotristat ethyl.<\/p>\n<h2 style=\"text-align: justify;\"><\/h2>\n","protected":false},"excerpt":{"rendered":"<p>Bayer Partners with DelSiTech to Develop Innovative Drug Delivery Technology for Ophthalmology Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology Licence Agreement. The agreement gives Bayer\u2019s compounds a worldwide application of DelSiTech\u2019s Silica Matrix drug delivery platform, especially in ophthalmology.\u00a0DelSiTech is entitled to receive a number [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1330,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[70,831,1962,96,107,17370,17371,17372,434,17373],"industry":[17226],"therapeutic_areas":[17242,17244],"class_list":["post-1327","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-allergan","tag-amgen","tag-arrowhead-pharmaceuticals","tag-astrazeneca","tag-bayer","tag-delsitech","tag-lexicon-pharma","tag-medi2070","tag-ophthalmology","tag-symphony-icon","industry-medical-devices","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bayer &amp; DelSiTech to Develop; Amgen and Arrowhead Announce<\/title>\n<meta name=\"description\" content=\"Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer &amp; DelSiTech to Develop; Amgen and Arrowhead Announce\" \/>\n<meta property=\"og:description\" content=\"Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-06T12:37:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/12051744\/innovation2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"240\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer & DelSiTech to Develop; Amgen and Arrowhead Announce","description":"Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6","og_locale":"en_US","og_type":"article","og_title":"Bayer & DelSiTech to Develop; Amgen and Arrowhead Announce","og_description":"Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology.....","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-10-06T12:37:18+00:00","article_modified_time":"2021-07-24T07:26:33+00:00","og_image":[{"width":400,"height":240,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/12051744\/innovation2.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6","name":"Bayer & DelSiTech to Develop; Amgen and Arrowhead Announce","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/12051744\/innovation2.jpg","datePublished":"2016-10-06T12:37:18+00:00","dateModified":"2021-07-24T07:26:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Bayer has partnered with a Finnish drug delivery and drug developmental company,DelSiTechLtd., through a Collaboration and Technology.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-6"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-6#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/12051744\/innovation2.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/12051744\/innovation2.jpg","width":400,"height":240},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/10\/12051744\/innovation2-300x180.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amgen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Arrowhead Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelSiTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lexicon Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MEDI2070<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthalmology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Symphony Icon<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Amgen<\/span>","<span class=\"advgb-post-tax-term\">Arrowhead Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">DelSiTech<\/span>","<span class=\"advgb-post-tax-term\">Lexicon Pharma<\/span>","<span class=\"advgb-post-tax-term\">MEDI2070<\/span>","<span class=\"advgb-post-tax-term\">Ophthalmology<\/span>","<span class=\"advgb-post-tax-term\">Symphony Icon<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 6, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 6, 2016 6:07 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1327"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1327\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1330"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1327"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1327"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}